Member Info for iaintgotaclu

Key bit for me :

Following this discovery, the researchers investigated the potential for 2,486 compounds already approved by the FDA for a number of different indications, to cause the CTC clusters to dissociate (break up into individual cells). They found a small number of drugs with the capability to do this. Once dissociated, they found that CTC clusters (now single cells) lost their high metastatic potential.

The directors believe that the results show exceptional promise for use in human cancer. The mechanism of action of the drugs was to effectively weaken the cell-cell connections in the CTC cluster rather than to kill the cancer cells. Conventional chemotherapy seeks to kill the cancer cell and is consequently inherently toxic, which is why patients can suffer serious side effects from the treatment as non-cancer cells may also be adversely affected. Further, conventional therapies aimed at killing cancer cells are prone to give rise to drug-resistant cell populations, which can ultimately lead to disease relapse. In contrast, the drugs used for the CTC cluster dissociation are already approved by the FDA for different non-cancer indications and do not have the typical side effects of chemotherapy or immunotherapy.

https://www.telegraph.co.uk/business/2019/01/10/biotech-minnow-angle-triumphs-cancer-blood-testing-kit/

What have a brought lol that was mental and impulsive

Well well with this and DNL a very good day.... where is this heading in the morning as most would have missed this news as late on

Angle PLC BREAKTHROUGH CANCER RESEARCH USING PARSORTIX

Angle PLC BREAKTHROUGH CANCER RESEARCH USING PARSORTIX

Source: UK Regulatory (RNS & others)
TIDMAGL

RNS Number : 7590M

Angle PLC

10 January 2019

For immediate release 10 January 2019

ANGLE plc ("the Company")

BREAKTHROUGH RESEARCH USING THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO TRANSFORM CANCER TREATMENT BY SUPPRESSING CANCER METASTASIS

Research using Parsortix to isolate CTC clusters from blood identifies drugs which dissociate highly metastatic CTC clusters resulting in a near total elimination of metastasis in animal models

Opportunity for Parsortix liquid biopsy to be routinely used to identify patients who may benefit from the new approach to suppress cancer metastasis

BOOOOOOOOOOOOOOOOOOM

Angle PLC BREAKTHROUGH CANCER RESEARCH USING PARSORTIX

Source: UK Regulatory (RNS & others)
TIDMAGL

RNS Number : 7590M

Angle PLC

10 January 2019

For immediate release 10 January 2019

ANGLE plc ("the Company")

BREAKTHROUGH RESEARCH USING THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO TRANSFORM CANCER TREATMENT BY SUPPRESSING CANCER METASTASIS

Research using Parsortix to isolate CTC clusters from blood identifies drugs which dissociate highly metastatic CTC clusters resulting in a near total elimination of metastasis in animal models

Opportunity for Parsortix liquid biopsy to be routinely used to identify patients who may benefit from the new approach to suppress cancer metastasis

Mexican standoff who moves first

gonna be a great last hour

Here we go

58 Ask

£5k buy coming in when its 140% they know exactly what they are doing

Big jump once 52 took out

Keep em peeled

Once the MMs have tidied up the books it could get jiggy

Topped up thanks mms

ask is rising funny that

Round 8 coming up and its gonna be a biggie

patmike
10 Jan '19 - 12:37 - 55 of 57
0 0 0
What a galactically stupid rns!!!
We`ve informed you of a US patent in a billion pound market, but we see no reason for the rise in sp. Durrrrrrrr...